Novo Nordisk Iran and the Food and Drug Administration of the Islamic Republic of Iran have signed a Memorandum of Understanding for the project, which is expected to be completed in five years.
The plant will manufacture Novo Nordisk’s FlexPen prefilled devices for,local use, creating 160 jobs. Construction is anticipated to start in six months.
Novo Nordisk Business Area Near East corporate vice president Ole Moelskov Bech said: "We are happy to commit to this manufacturing facility in Iran. It signals our long-term commitment to Iran, a country where close to 5 million people have diabetes according to the International Diabetes Federation.
"This investment will ensure availability of our modern insulins and will bring us a step closer to the people who rely on our products."
Novo Nordisk currently employs about 130 people in Iran. The company has been producing devices in the country since 2002 via a local partner.
Novo Nordisk employs about 39,700 people in 75 countries and markets its products in over 180 countries.
Image: Novo Nordisk headquarters in Denmark. Photo: courtesy of Novo Nordisk A/S.